"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

Barbara Salami is the VP of Digital for Commercial at Moderna where she is leads digital transformation for Moderna’s new ...

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Georgia has suspended all poultry activities after bird flu was confirmed during a commercial poultry operation. The positive ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...